SCHEMBL19958499

SCHEMBL19958499

CC(=O)NCCCCCNC(=O)CCC(=O)NCCCCCNC(=O)CCC(=O)NCCCCCN

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAOX Q6QHF9 5/20 0.81
▸ HIF1A Q16665 2/20 0.61
▸ KDM4E B2RXH2 2/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ KDM4A O75164 1/20 0.59
▸ TET2 Q6N021 1/20 0.59
▸ DOHH Q9BU89 1/20 0.59
▸ SLC6A5 Q9Y345 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ ADRA1A P35348 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ CASP2 P42575 1/20 0.50
▸ NAAA Q02083 1/20 0.47
▸ SIRT6 Q8N6T7 1/20 0.45
▸ SIRT1 Q96EB6 1/20 0.45
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GNAI3 P08754 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22211260 1.00 PAOX (0.81) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL1409002 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL19816770 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL346746 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL1408891 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL285321 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL7552315 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL21842271 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL12006469 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A
SCHEMBL1409041 0.90 PAOX (1.00) PAOXHIF1AKDM4EMAPK1KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3983020-B1 AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO TAGWORKS PHARMACEUTICALS B V (NL) 2024-06-26 — — EP disclosed
US-20180071265-A1 Method of Treating or Preventing Pathologic Effects of Acute Increases in Hyperglycemia and/or Acute Increases of Free Fatty Acid Flux GURTNER, GEOFFREY C. 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071265-A1 Method of Treating or Preventing Pathologic Effects of Acute Increases in Hyperglycemia and/or Acute Increases of Free Fatty Acid Flux ATF4, NOX4, ATF1 PAOX 203/4885HIF1A 311/4885KDM4E 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback